Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Paliperidone impurity 8 hydrochloride is a drug impurity associated with paliperidone hydrochloride. This compound is primarily used for quality control in pharmaceutical research and development, particularly in the analysis and characterization of antipsychotic medications. Its presence can affect the efficacy and safety profiles of the parent compound, making it essential for evaluating metabolic pathways and ensuring pharmaceutical compliance. -
Drug Impurity
Tamsulosin impurity 13 is a pharmaceutical impurity associated with Tamsulosin. This compound is utilized primarily for analytical research, particularly in assessing the purity of Tamsulosin in pharmaceutical formulations. It serves as a reference standard for stability studies and quality control, aiding in the compliance with regulatory guidelines for drug development. -
Drug Impurity
Ropinirole impurity 11 is identified as a chemical impurity associated with the synthesis of Ropinirole. This compound is utilized primarily in quality control and analytical chemistry to assess the purity of Ropinirole formulations. It serves as a reference standard for researchers investigating the implications of impurities in pharmaceutical development and safety studies. -
Drug Impurity
Famotidine impurity 9, also known as Famotidine cyanoamidine, is a drug impurity associated with Famotidine. This compound is of significant interest for researchers monitoring the quality and integrity of pharmaceutical formulations. Its characterization supports studies evaluating the stability and safety profiles of Famotidine-based therapies. -
Drug Impurity
Bupropion impurity 19 is a known impurity of the antidepressant Bupropion. As a chemical research reagent, it serves as an important tool for analytical and developmental studies in pharmaceutical research. Its presence and characterization are essential for ensuring the quality and safety of Bupropion formulations, contributing to the understanding of drug metabolism and formulation integrity. -
Drug Impurity
Esomeprazole impurity 1 is a known impurity of the proton pump inhibitor Esomeprazole, primarily affecting gastric acid secretion. This compound serves as a crucial reference standard for analytical and quality control studies, facilitating the assessment of Esomeprazole purity and stability in pharmaceutical formulations. It is relevant in pharmacokinetic studies and method development for detecting impurities in drug substances. -
Drug Impurity
Rebamipide impurity 5 is a chemical impurity related to the pharmaceutical compound Rebamipide. This impurity is primarily utilized in the analysis and quality control of Rebamipide formulations. Research applications include method development for impurity profiling and assessing the stability and purity of drug substances in pharmaceutical studies. -
Drug Impurity
Beclometasone dipropionate impurity 6, also known as Beclomethasone 11,17,21-tripropionate, is a drug impurity related to Beclometasone dipropionate. This compound serves as a critical marker in assessing the purity of Beclometasone dipropionate in pharmaceutical formulations. Its identification and quantification are essential for quality control and regulatory compliance in drug development and manufacturing processes. -
Drug Impurity
Aripiprazole impurity 29 is a synthetic byproduct of Aripiprazole, a medication primarily utilized in the treatment of schizophrenia and bipolar disorder. This reagent serves as a reference standard for analytical methods aimed at assessing the purity of Aripiprazole formulations. Its role in drug development and quality control ensures compliance with pharmaceutical regulations. -
Drug Impurity
Rivaroxaban impurity 15 is a characterized impurity associated with the anticoagulant Rivaroxaban. This compound is crucial for quality control and validation in pharmaceutical research and development, enabling scientists to understand its effects on drug stability and efficacy. It serves as a reference standard in analytical chemistry for assessing the purity of Rivaroxaban formulations in compliance with regulatory standards. -
Drug Impurity
Rivaroxaban impurity 25 is a known impurity associated with the anticoagulant Rivaroxaban. It is primarily utilized in analytical and quality control settings for the assessment of drug purity and stability. The characterization of this impurity is essential for ensuring compliance with regulatory standards and understanding the compound's overall pharmacological profile. -
Drug Impurity
Methylprednisolone impurity 7 is a known impurity of the corticosteroid Methylprednisolone. This compound is utilized primarily in the pharmaceutical industry for stability testing and quality control assessments. Its identification and quantification are crucial for ensuring the purity and safety of corticosteroid preparations in clinical applications and research. -
Drug Impurity
Candesartan impurity 19 is a characterized impurity associated with the angiotensin II receptor blocker, Candesartan. This compound is utilized for analytical and quality control purposes in pharmaceutical research to ensure the purity and safety of Candesartan formulations. Its presence can impact the overall pharmacological profile of drug products, making it significant for studies focused on drug formulation and regulatory compliance. -
Drug Impurity
Quetiapine impurity 9, identified as a specific drug impurity of Quetiapine, serves as an essential reference standard in pharmaceutical research. Its analysis is critical for assessing the purity and quality of Quetiapine formulations. This impurity aids in the development of reliable analytical methods and ensures compliance with regulatory requirements in drug manufacturing and safety evaluation. -
Oseltamivir Impurity
4-N-Desacetyl-5-N-acetyl oseltamivir is an impurity of Oseltamivir, a neuraminidase inhibitor primarily used in the treatment of influenza. This compound can be utilized in quality control and analytical studies related to the synthesis and stability of Oseltamivir. Its identification and characterization are essential for ensuring the purity and efficacy of antiviral formulations. -
Drug Impurity
Palbociclib impurity 20 is a known impurity of the CDK4/6 inhibitor palbociclib, a key compound in the treatment of various cancers. This reagent is essential for quality control and stability studies in pharmaceuticals, enabling researchers to evaluate the purity and safety of drug formulations. Its analysis is crucial in ensuring compliance with regulatory standards in the development of palbociclib-based therapies. -
Drug Impurity
Estradiol Valerate impurity 1 is a known impurity associated with the synthetic steroid hormone Estradiol Valerate. Its characterization is essential in assessing the purity and quality of pharmaceutical preparations containing Estradiol Valerate. This compound can be utilized in analytical chemistry, particularly in method development and validation for ensuring compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Levothyroxine impurity 2 is a recognized impurity associated with levothyroxine, a synthetic form of the thyroid hormone thyroxine. This compound serves as a reference standard for quality control and analytical studies in pharmaceutical development. Researchers utilize this impurity to ensure the purity and efficacy of levothyroxine formulations in compliance with regulatory standards. -
Drug Impurity
Alfuzosin EP impurity 5 is a chemical impurity associated with Alfuzosin EP, a medication primarily used as an alpha-1 adrenergic antagonist. This compound is essential for quality control and analytical studies in pharmaceutical research. It serves as a reference standard for assessing the purity of Alfuzosin EP during drug formulation and stability testing. -
Drug Impurity
Pantoprazole impurity 5 (N1-Methyl pantoprazole) is a known impurity of the proton pump inhibitor Pantoprazole. This compound may be utilized in analytical studies to assess the quality and stability of Pantoprazole formulations. Research applications include impurity profiling and evaluation of pharmaceutical manufacturing processes. -
Drug Impurity
Fusidic acid impurity 8 is a byproduct associated with the synthesis of Fusidic acid. This compound serves as a valuable reference standard for analytical methodologies aimed at assessing the purity and quality of Fusidic acid formulations. Its presence can impact pharmacological properties and is relevant for regulatory compliance in drug development and quality control processes. -
Drug Impurity
Tazobactam impurity 13 is a chemical impurity associated with Tazobactam, a β-lactamase inhibitor. This compound can be utilized in the characterization and quality control of Tazobactam formulations, thereby supporting analytical research and regulatory compliance in pharmaceutical development. Its identification is crucial for ensuring the purity and safety of drug products containing Tazobactam. -
Drug Impurity
Escitalopram impurity 4 is a known impurity of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Its presence can be significant in the assessment of drug quality and safety, particularly in pharmacokinetic studies. This reagent may be used in research focused on drug formulation, stability testing, and analytical chemistry to ensure compliance with regulatory standards. -
Drug Impurity
Betamethasone impurity 3 is a recognized impurity of the corticosteroid drug Betamethasone. As a compound, it serves as a useful reference standard in analytical chemistry and quality control processes to evaluate the purity of Betamethasone formulations. Researchers employ this impurity in various studies focusing on drug stability, efficacy, and safety assessments within pharmaceutical development. -
Drug Impurity
Donepezil impurity 9, also known as Donepezil impurity G, is a drug impurity associated with the synthesis of Donepezil. This compound is utilized in quality control and stability studies of Donepezil formulations. Research applications include the assessment of purity and identification of synthetic by-products, which are essential for ensuring the safety and efficacy of pharmaceutical products. -
Drug Impurity
Mesalazine impurity 10 (N-Propionyl Mesalazine) is a known impurity of the anti-inflammatory drug Mesalazine. This compound may be utilized in drug development and quality control to assess the purity and safety of Mesalazine formulations. Its presence can impact the efficacy and side effect profile of pharmaceutical preparations, making it relevant for analytical and regulatory assessments in pharmaceutical research. -
Drug Impurity
Mirabegron impurity 12 is a known impurity associated with the pharmaceutical compound Mirabegron, which primarily acts as a β3-adrenergic receptor agonist. This impurity may be important for analytical characterization and quality control in pharmaceutical research and development. Its detection and quantification can aid in understanding the safety and efficacy profiles of Mirabegron formulations. -
Drug Impurity
Olmesartan impurity 4 is a specified impurity associated with Olmesartan, an angiotensin II receptor antagonist used primarily for the treatment of hypertension. This impurity can serve as an important analytical standard in pharmaceutical research and development, aiding in the assessment of drug purity and quality control. Its analysis is essential for ensuring compliance with regulatory standards and for understanding the implications of impurities on drug efficacy and safety. -
Drug Impurity
Rosuvastatin impurity 38 calcium is a known impurity associated with Rosuvastatin calcium, a medication commonly used to lower cholesterol levels. This compound serves as a reference standard for the identification and quantification of impurities during pharmaceutical analysis. Its biological activity may offer insights into the safety and efficacy profiles of Rosuvastatin formulations in research applications. -
Drug Impurity
Ketoconazole impurity 5 is a known impurity of the antifungal agent ketoconazole. This compound is utilized in analytical chemistry to assess the purity and quality of pharmaceutical formulations containing ketoconazole. It serves as a crucial reference standard for ensuring compliance with regulatory guidelines in drug development and quality control. -
Drug Impurity
Azilsartan impurity 32 is a chemical impurity associated with Azilsartan, an antihypertensive agent that primarily targets the angiotensin II receptor. This impurity is relevant for analytical and quality control applications in the pharmaceutical industry, facilitating the assessment of drug purity and compliance with regulatory standards. It is essential for researchers conducting stability studies and formulation development involving Azilsartan. -
Drug Impurity
Meloxicam impurity 6 is a characterized impurity of the non-steroidal anti-inflammatory drug Meloxicam. It serves as a valuable reference standard for quality control and method development in pharmaceutical analysis. This impurity is important for understanding the chemical profile of Meloxicam and ensuring the integrity of formulations in drug development studies. -
Drug Impurity
Cinacalcet impurity 13 is a known impurity associated with the drug Cinacalcet, which acts as a calcimimetic agent targeting the calcium-sensing receptor (CaSR). This impurity may be generated during the synthesis of Cinacalcet and is useful for analytical and quality control purposes in pharmaceutical development. Researchers can utilize this compound to assess the purity and stability of Cinacalcet formulations in regulatory submissions. -
Drug Impurity
Diclofenac Impurity 6 is a chemical impurity associated with Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID). This impurity is significant for analytical research and quality control in pharmaceutical development, aiding in the assessment of drug purity and stability. Its presence may impact the pharmacological properties of Diclofenac, making it essential for studies focused on drug formulation and regulatory compliance. -
Drug Impurity
Albendazole Impurity 3 is a known impurity associated with the anthelmintic agent Albendazole. This compound is primarily investigated for its role in assessing the purity and stability of Albendazole formulations. Its identification is essential for quality control and regulatory compliance in drug development and manufacturing processes. -
Drug Impurity
Atenolol impurity 7 is a known impurity associated with the beta-blocker Atenolol. Its characterization is crucial for ensuring the quality and safety of Atenolol formulations. Researchers utilize this compound to investigate the effects of impurities on drug efficacy and stability, aiding in the development of more robust pharmaceutical formulations. -
Drug Impurity
Quetiapine impurity 16 is a known impurity of the atypical antipsychotic quetiapine. It is primarily utilized in pharmacological studies to assess the purity and quality of quetiapine formulations. This compound plays a crucial role in understanding the chemical profile and potential effects of quetiapine in therapeutic contexts. Analytical methods such as HPLC may be employed for its detection and quantification in drug development processes. -
Drug Impurity
Ibuprofen impurity 9 is identified as a degradation product of ibuprofen. This compound serves as a critical reference standard for quality control in pharmaceutical formulations and helps in the assessment of drug purity. Its analysis is essential for ensuring compliance with regulatory standards in drug development and manufacturing processes. -
Drug Impurity
Neratinib impurity 13 is a chemical impurity associated with the anti-cancer agent Neratinib. As a drug impurity, it provides critical insights into the stability and quality control of Neratinib formulations. It serves as an important reference standard for analytical and formulation studies, assisting in the evaluation of drug efficacy and safety. -
Drug Impurity
Rivaroxaban impurity 45 is a known impurity of the anticoagulant drug Rivaroxaban, which acts as a direct factor Xa inhibitor. This compound is essential for the analysis of drug quality and purity, serving as a reference standard in pharmaceutical and biochemical research. Its characterization is critical for the development of analytical methods and for ensuring compliance with regulatory standards in clinical studies and drug manufacturing processes. -
Drug Impurity
Azithromycin impurity 23 is identified as a minor impurity related to the antibiotic Azithromycin. Its presence is relevant for drug quality control and analysis, particularly in pharmaceutical research and development settings. This impurity can affect the overall purity and efficacy of Azithromycin, making it crucial for studies focused on drug formulation and stability. -
Drug Impurity
Duloxetine impurity 14, also known as Duloxetine succinamide, is a chemical impurity associated with the synthesis of Duloxetine. It serves as a crucial reference standard for assessing the purity and quality of Duloxetine in pharmaceutical formulations. Research applications include method development and validation in analytical chemistry, as well as stability studies of Duloxetine-containing products. -
Drug Impurity
Famotidine impurity 2, also known as Famotidine impurity A, is a chemical impurity associated with the pharmaceutical compound Famotidine. Its presence is essential for analytical and quality control applications in drug development processes. This impurity serves as a critical reference standard for the assessment of Famotidine's purity and compliance with regulatory standards during formulation and stability studies. -
Drug Impurity
Telmisartan impurity 1, also known as 4'-Bromomethyl-2-cyanobiphenyl, serves as a drug impurity associated with Telmisartan. This compound is significant for quality control in pharmaceutical formulations and is utilized in the development and validation of analytical methods for telmisartan quantification. Its characterization can aid in assessing the purity and stability of telmisartan during research and production processes. -
Drug Impurity
Ranitidine impurity 14 is a known impurity associated with the drug Ranitidine. This compound is utilized primarily in analytical research to assess the purity and quality of pharmaceutical formulations containing Ranitidine. Its presence can impact drug efficacy and safety, making it significant for quality control and regulatory compliance in drug development. -
Drug Impurity
Paliperidone impurity 8 is a known impurity associated with the antipsychotic medication Paliperidone. It is utilized primarily in the quality control and regulatory compliance of pharmaceutical formulations to ensure the purity and safety of the drug. This reagent serves as an essential reference standard for analytical methods, including chromatography, to assess the presence and concentration of this impurity in drug products. -
Drug Impurity
Dacomitinib impurity 14 is identified as a chemical impurity associated with Dacomitinib, a pan-ErbB receptor tyrosine kinase inhibitor. The presence of this impurity is relevant for the characterization and quality control of Dacomitinib in pharmaceutical formulations. This reagent may be utilized in research studies focused on the analytical profiling and assessment of drug purity, as well as in the development of related therapeutic agents. -
Drug Impurity
Sorafenib impurity 5 is a defined impurity of the multi-kinase inhibitor Sorafenib, primarily targeting RAF kinases, VEGFR, and PDGFR. This reagent is essential for quality control and analytical purposes in pharmaceutical research, enabling the assessment of purities in the synthesis of Sorafenib. It aids researchers in understanding the chemical composition and potential impacts of impurities on drug efficacy and safety profiles. -
Drug Impurity
Brimonidine impurity 3 is a chemical impurity associated with the drug Brimonidine, primarily targeting adrenergic receptors. This compound is relevant for quality control in pharmaceutical formulations and can be utilized to study the stability and degradation pathways of Brimonidine. Its characterization contributes to the development of safer and more effective drug products. -
Drug Impurity
Tandospirone impurity 3 is a chemical impurity associated with the drug Tandospirone, a known anxiolytic agent targeting serotonin receptors. This impurity is critical for quality control and analytical research, ensuring the integrity and safety of pharmaceutical formulations containing Tandospirone. Its characterization can aid in understanding the metabolic pathways and potential effects of Tandospirone in various biological contexts.
